Stay Informed: Transforming Radiology with Structured Reporting and Data-Driven Approaches

Dive into our activities, projects, and product updates. Catch on the latest industry news and learn who we are as a company and as a team.

Doctors looking at MRI scans to evaluate a glioblastoma.

Optimizing Glioblastoma Imaging: Enhancing MRI Efficiency and Quality with Deep Learning

This study investigates the use of deep learning (DL) to optimize MRI protocols for glioblastoma patients, aiming to reduce scan time and improve image quality.

Glioblastomas are aggressive brain tumors requiring frequent MRI monitoring, which can be challenging due to lengthy scan times and motion artifacts. Traditional methods to shorten scan times, like parallel acquisition techniques (PAT) and compressed sensing (CS), have limitations such as reduced signal-to-noise ratio and overly smooth images.

The study, involving 33 patients, found that DL-optimized MRI sequences reduced scan time by 30% while enhancing image quality and maintaining diagnostic accuracy. These improvements are particularly beneficial for patients who struggle with lengthy MRI procedures, offering a promising advancement in glioblastoma care.

Read more about the study here.

Related Resources

Related Resources

Hands holding a glass lung

Comparison of iRECIST and RECIST 1.1 for Evaluating Immunotherapy in Melanoma and Non-Small Cell Lung Cancer

In a retrospective study conducted at the University Hospital Cologne, the radiological criteria iRECIST and RECIST 1.1 were compared for assessing…

Image shows graphic related to study's research on iRECIST and RECIST

University Hospital Cologne: Comparison of iRECIST and RECIST 1.1 for Evaluating Immunotherapy in Melanoma and Non-Small Cell Lung Cancer

A retrospective study conducted at University Hospital Cologne compared two criteria for assessing therapeutic response to immunotherapy: iRECIST and…

Doctors holding up puzzle pieces

Developing Standardized Reporting Templates for Sarcomas: Insights from Prof. Dr. Wolfgang Kunz

Sarcomas are a rare and heterogeneous group of malignant tumors that pose significant challenges in both diagnosis and treatment. Within the framework…